BiotechTube

SHR8028 eye drops + Vehicle eye drops.

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

Mar 4, 2021 → Jul 22, 2022

NCT ID
NCT05841043

About SHR8028 eye drops + Vehicle eye drops.

SHR8028 eye drops + Vehicle eye drops. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05841043. Target conditions include Dry Eye Disease.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Disease were approved

Approved (20) Terminated (1) Active (0)
✅EvolocumabHeartFlowApproved
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅YMC026 + PlaceboYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05841043Phase 3Completed

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
mRNA-1975ModernaPhase 2
0
mRNA-3745ModernaPhase 2
0
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
UB-312 + PlaceboVaxxinityPhase 1
19
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
21
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
26
LanifibranorInventivaPhase 2
29
LY450139 + PlaceboEli LillyPhase 3
40
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
Solanezumab + PlaceboEli LillyPhase 3
32